Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03887520 · ClinicalTrials.gov registry record · NA
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
A NA study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 49,001
- Enrollment target
NCT03887520 is a NA study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 49,001 participants.
The verdict
NCT03887520, a NA study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 49,001 participants
- Enrollment target
Study Summary
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
Interventions
- DIAGNOSTIC_TEST Blood draw for Lp(a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,001 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2021-07-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03887520
The ClinicalTrials.gov registry entry for NCT03887520 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49,001 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw for Lp(a) is the first listed.
NCT03887520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03887520 about?
NCT03887520 is a clinical study titled "Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)". The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
What is the current status of trial NCT03887520?
This trial is currently completed. It is a NA study. The enrollment target is 49,001 participants. The study started on 2018-11-27. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT03887520?
The interventions under investigation include: Blood draw for Lp(a) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03887520?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.